drugset / Trial / NCT00575666
Intranasal Insulin Treatment in Patients With Schizophrenia
Phase 4
Completed
45 enrolled
University of Massachusetts, Worcester
Eli Lilly and Company · collabNational Alliance for Research on Schizophrenia and Depression · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is an 8-week, randomized, double-blind, placebo-controlled trial of intranasal insulin as an adjunctive therapy, with a 4-week follow-up, in 60 non-diabetic schizophrenia subjects to examine insulin's effect on psychopathology and cognition. In addition, the study will examine insulin's effects on weight, food intake, resting energy expenditure, and body composition.
Timeline
- Start
- 2007-12
- Primary completion
- 2010-09
- Completion
- 2010-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin | Protein / enzyme biologic | 40 iu | Intranasal |